# A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT00474188** · PHASE2 · TERMINATED · sponsor: **Celgene Corporation** · enrollment: 26 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** CC-5013 (lenalidomide)
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00474188
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2009-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00474188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00474188, "A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00474188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*